FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

STATEMENT	OF CHANGES	IN BENEFICIAL	OWNERSHIP

OMB APPROVAL											
OMB Number:	3235-0287										
Estimated average b	ourden										
hours per response:											

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person* Bonnell Brian Michael (Last) (First) (Middle) 951 CALLE AMANECER (Street) SAN CLEMENTE CA 92673 (City) (State) (Zip)					3. 03	2. Issuer Name and Ticker or Trading Symbol ICU MEDICAL INC/DE [ICUI] 3. Date of Earliest Transaction (Month/Day/Year) 03/06/2020 4. If Amendment, Date of Original Filed (Month/Day/Year)									6. Inc Line)	Relationship of Reporting Person(s) to Issuer Check all applicable) Director 10% Owner X Officer (give title Other (specify below) Chief Financial Officer Individual or Joint/Group Filing (Check Applicable ine) X Form filed by One Reporting Person Form filed by More than One Reporting Person				
	Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned																			
1. Title of Security (Instr. 3) 2. Transa Date (Month/D				Execution Date,		Code (Instr. 5)		es Acquii Of (D) (In:	ed (A) str. 3,	or 4 and	5. Amour Securities Beneficia Owned Fe	s Illy ollowing	Form	: Direct Indirect str. 4)	7. Nature of Indirect Beneficial Ownership					
									-	Code	v	Amount	(A) o	r P	rice	Reported Transacti (Instr. 3 a	on(s)			(Instr. 4)
Common Stock 03/06				06/202	2020			M		722			\$0.0	722		D				
Common Stock 03/06			06/202	′2020			F		377 D			\$0.0	345			D				
	Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)																			
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution D if any (Month/Day/	Date,	4. Transa Code (8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		Expir	6. Date Exercisab Expiration Date (Month/Day/Year)		e and	7. Title and Amount of Securities Underlying Derivative Sec (Instr. 3 and 4)		urity	8. Price of Derivative Security (Instr. 5)	9. Number derivative Securities Beneficial Owned Following Reported Transactio (Instr. 4)	e s Illy	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	Beneficial Ownership (Instr. 4)
					Code	v	(A)	(D)	Date Exerc	cisable	Expi Date	iration	Title	or Nu of	nount mber ares					
Common Stock ⁽¹⁾	\$0.0 ⁽²⁾	03/06/2020			M			722		(3)	03/0	06/2022 ⁽⁴⁾	Common Stock	7	22	\$0.0	1,444		D	
Common Stock ⁽¹⁾	\$0.0 ⁽²⁾	03/06/2020			M		4,652		((3)	03/	/06/2023	Common	4,	652	\$0.0	4,652		D	

Explanation of Responses:

- 1. These securities are Restricted Stock Units.
- 2. There is neither a purchase price nor an exercise price for the Restricted Stock Units.
- 3. One third of the units subject to the award shall vest on each of the first, second, and third anniversaries of the grant date.
- 4. These are restricted stock units that fully vest 3 years from the grant date.

By: Paula Darbyshire,

Attorney-in-fact For: Brian

Bonnell

** Signature of Reporting Person Date

03/10/2020

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.